L-MTP-PE

PreclinicalSmall molecule

MMemorial Sloan Kettering Cancer Center

L-MTP-PE is one of 51 small molecule programs targeting Osteosarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteosarcomaActive, not recruiting

OsteosarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Osteosarcoma

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

17 2

Ifex

BBaxter Healthcare Corporation

Phase 3

18 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

17 4

Vepesid

AAvyxa

Phase 3

12 5

Adriamycin

GGynecologic Oncology Group

Phase 3

10 6

PEG-Intron

Merck & Co.

Phase 3

1 7

Adriamycin

Pfizer

Phase 2

6 8

Standard Chemotherapy

Roche

Phase 3

1 9

Cabometyx

Bristol-Myers Squibb

Phase 2

3 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteosarcoma1 trial

Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma

Available·MMemorial Sloan Kettering Cancer Center··NCT04571229

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for L-MTP-PE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-MTP-PE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-MTP-PE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMemorial Sloan Kettering Cancer Center

L-MTP-PE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteosarcoma1 trial

References

Drug Info

Quick Facts

Related News